Cerity Partners LLC 购入了 45,890 股伊克力西斯公司（纳斯达克股票代码：EXEL）

Cerity Partners LLC grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 163.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 73,884 shares of the biotechnology company's stock after acquiring an additional 45,890 shares during the quarter. Cerity Partners LLC's holdings in Exelixis were worth $2,413,000 as of its most recent SEC filing.

• 3 Stocks to Buy for a Soft Landing, If There Is One

A number of other hedge funds also recently modified their holdings of EXEL. FMR LLC grew its stake in Exelixis by 19.7% during the fourth quarter. FMR LLC now owns 2,947,599 shares of the biotechnology company's stock worth $98,155,000 after buying an additional 485,527 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of Exelixis by 82.9% in the 4th quarter. Federated Hermes Inc. now owns 408,932 shares of the biotechnology company's stock valued at $13,637,000 after purchasing an additional 185,389 shares during the last quarter. Hurley Capital LLC acquired a new position in Exelixis during the fourth quarter worth about $68,000. Envestnet Asset Management Inc. increased its position in Exelixis by 17.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 200,228 shares of the biotechnology company's stock worth $6,668,000 after purchasing an additional 29,892 shares in the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC lifted its stake in shares of Exelixis by 80.2% in the 4th quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 151,153 shares of the biotechnology company's stock valued at $5,033,000 after acquiring an additional 67,256 shares during the last quarter. Institutional investors own 85.27% of the company's stock.

Insider Transactions at Exelixis

In other news, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the transaction, the director now owns 356,605 shares in the company, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the sale, the executive vice president now owns 303,310 shares of the company's stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

• 3 Strong Biotech Performers To Watch As Sector Nears Breakout

Several equities analysts have issued reports on EXEL shares. JMP Securities restated a "market outperform" rating and issued a $41.00 price target on shares of Exelixis in a research report on Thursday, January 23rd. Guggenheim restated a "buy" rating and set a $42.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Stifel Nicolaus lifted their target price on Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a report on Wednesday, February 12th. Morgan Stanley upgraded Exelixis from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $30.00 to $40.00 in a report on Monday, January 27th. Finally, Bank of America lowered Exelixis from a "buy" rating to a "neutral" rating and boosted their target price for the company from $35.00 to $39.00 in a research report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $37.59.

View Our Latest Analysis on Exelixis

Exelixis Stock Up 2.2 %

• 7 Best Cancer Stocks to Invest in Now

NASDAQ EXEL opened at $36.54 on Wednesday. The stock's 50-day simple moving average is $36.26 and its two-hundred day simple moving average is $34.09. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02. The company has a market capitalization of $10.23 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, equities analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

See Also

• Five stocks we like better than Exelixis
• What Is WallStreetBets and What Stocks Are They Targeting?
• Beware of BigBear.ai: Insiders Are Selling—Should You?
• Election Stocks: How Elections Affect the Stock Market
• CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
• Growth Stocks: What They Are, What They Are Not
• Congress! Who Traded What During the Tariff-Induced Meltdown

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Exelixis Right Now?

Before you consider Exelixis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.

While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here